National Study for Prevention of Embolism in Atrial Fibrillation "NASPEAF"


Phase N/A Results


The combined therapy proved to be the most efficacious and safer treatment and, as compared to the anticoagulant therapy, decreased the aggregate embolism, stroke, and rate of TIA by 56% in the intermediate and high-risk groups. There were a total of 42 severe bleeding episodes (with significantly fewer episodes in the antiplatelet arm as opposed to the anticoagulant and combined therapy arms). 14 of these episodes were intracranial (2 in the antiplatelet arm, 9 in the anticoagulant, and 3 in the combined arm) and 15 were gastric, mostly in the combined therapy arms. Primary outcomes were lower in the combined therapy group compared to the anticoagulant group (p = .02 in the intermediate group and p = .03 in the high risk group).